Lisa R. Bulkow

Antibody Levels and Protection after Hepatitis B Vaccination: Results of a 15-Year Follow-up

Context Although administration of hepatitis B vaccine for infants is routine practice in many countries, we do not know whether the protection that this vaccine offers lasts beyond 10 years. Such information is essential to develop policies about booster vaccination. Contribution Of 841 Alaska Natives who received 3 doses of hepatitis B vaccination during 19811982 and were followed for 15 years, 84% had protective levels of antibody to hepatitis B surface antigen that indicated continued protection. The greatest decline in antibody levels occurred in people who received vaccine before 4 years of age. Definite asymptomatic breakthrough infections occurred in 16 participants. Cautions Only about half of the initial cohort of 1578 was available for testing at 15 years. The Editors Universal vaccination of infants with hepatitis B vaccine is included in the immunization programs of most countries and has been shown to be effective in reducing the rate of chronic hepatitis B virus (HBV) infection (1, 2). Protection has been demonstrated in persons and populations vaccinated for 5 to 10 years, and rates of asymptomatic breakthrough HBV infection have been extremely low (3-9). However, the duration of protection afforded by hepatitis B vaccination beyond 10 years and the possible need for booster doses of this vaccine are unknown. Alaska Natives have a high prevalence of chronic HBV infection, primarily acquired during early childhood (10). Between November 1981 and May 1982, Alaska Natives residing in 15 villages in southwest Alaska were enrolled in a cohort study to ascertain the immunogenicity and long-term effectiveness of hepatitis B vaccination (11-14). We report data on the persistence of antibodies to hepatitis B surface antigen (anti-HBs), incidence of HBV infection, and the genetic characteristics of the HBV isolates in persons with breakthrough infections 15 years after initial vaccination of this cohort. Methods Participants and Data Collection A total of 1578 Alaska Natives who were serologically negative for hepatitis B surface antigen (HBsAg) and antibody to hepatitis B core antigen (anti-HBc) were vaccinated on a 0-, 1-, and 6-month schedule with 3 doses of plasma-derived hepatitis B vaccine (Heptavax, Merck & Co., Inc., West Point, Pennsylvania) beginning in 1981 (11). Persons younger than 20 years of age received the 10-g dose, and adults received the 20-g dose. Of the 1578 persons vaccinated, 1436 (91%) were tested for an anti-HBs response 6 months after the last vaccine dose. From 1982 to 1992, serum specimens were obtained annually and once again during 1996 from as many of the 1578 consenting participants as possible. The Institutional Review Boards of the Alaska Area Native Health Service, the Indian Health Service, the Centers for Disease Control and Prevention, and the Yukon-Kuskokwim Health Corporation and the Norton Sound Regional Alaska Native health boards approved this study. All participants 18 years of age and older and parents of children younger than 18 years of age had provided signed informed consent to participate in the study; children older than 7 years of age gave verbal assent. The number of HBsAg-positive persons in each village was obtained from a registry used to follow patients with chronic HBV infection (15). Serologic Testing All serum specimens were tested for HBsAg, anti-HBs, and anti-HBc by radioimmunoassay using commercial test kits (Abbott Laboratories, Abbott Park, Illinois). At the initial testing of the cohort for anti-HBs, results were reported in sample ratio units. However, subsequent anti-HBs results were reported in milli international units (mIU) per mL using a World Health Organization reference standard (12-14). To ensure comparability of results over time, all serum specimens from each participant with sufficient volume (99.9% of all specimens collected during the study) were retested to determine anti-HBs levels in mIU/mL. Detection of HBV DNA and Nucleic Acid Sequencing Hepatitis B virus DNA was extracted from serum specimens (50 L) of participants with serologic markers of HBV infection by using commercially available reagents (MasterPure Complete DNA and RNA Purification Kit, Epicentre Technologies, Madison, Wisconsin), as described previously (16, 17). The HBsAg genomic region was then amplified by dilution cloning polymerase chain reaction by using previously described primers and methods to identify circulating variants of HBsAg (16, 17). The polymerase chain reaction products were purified and the nucleic acid sequence of the amplified region were determined by using prism dye or dRhodamine terminator cycle reactions (Applied Biosystems, Foster City, California) and automated sequencing (ABI Model 373 or 377, Applied Biosystems) (18). Sequence data were further analyzed by Sequence Navigator (ABI) and GCG software (19). Definitions The initial anti-HBs level was measured 6 months after the third dose of vaccine and 1 year after the first dose of vaccine. Participants with an initial anti-HBs level of at least 10 mIU/mL were considered vaccine responders. An anti-HBs level of 2 mIU/mL or greater was considered a positive result on subsequent specimens. A booster response was defined as a 2-fold or greater increase in anti-HBs levels between serologic test results. A definite HBV infection in a participant was defined as 1) 2 or more consecutive serum specimens positive for anti-HBc more than 1 year after the initial vaccine dose, 2) a single positive anti-HBc result with a positive HBV DNA result, or 3) any HBsAg-positive test result. A possible HBV infection was defined as a single positive or 2 nonconsecutive positive anti-HBc results. Participants who developed anti-HBc were interviewed for history of icterus or other clinical signs or symptoms compatible with acute hepatitis, and village and hospital medical records were reviewed for evidence of an illness compatible with viral hepatitis. Statistical Analysis Among persons who inadvertently received additional doses of hepatitis B vaccine during the follow-up period, anti-HBs results after the additional vaccine dose or doses were excluded from the analyses. Results for anti-HBs among persons with definite HBV infections were excluded from analyses after anti-HBc appeared. The primary outcomes in this study were the cumulative number of persons with a definite HBV infection during all follow-up years and the anti-HBs levels at the 15-year follow-up. The definitions of age classes (0 to 4 years, 5 to 19 years, 20 to 49 years, 50 years) were similar to those in a previously published analysis of this cohort (14). Although these data have been presented previously (11-14), we have provided the proportion of persons initially responding to vaccination. Quantitative anti-HBs levels are presented as geometric mean concentrations (GMCs). In bivariate analyses, analysis of variance was used to test the 15-year anti-HBs concentrations (log-transformed). Incidence rates of definite HBV infection were compared by using the Fisher exact test. We analyzed factors associated with anti-HBs levels over the 15 years after the first vaccine dose by using a linear mixed model (PROC MIXED in SAS version 9.1, SAS Institute, Inc., Cary, North Carolina) (19). We chose a longitudinal mixed linear model because it makes inferences by using information from the entire cohort collected at all follow-up time points. Levels of anti-HBs were log-transformed before analysis, and concentrations of 0 mIU/mL were assigned a value of 1.0 mIU/mL. Factors considered in the model were time (entered as a continuous covariate; linear and quadratic term were considered), age class at initial vaccination, sex, the log of the initial anti-HBs level, presence of an HBsAg-infected person in the household at the start of the study, and the proportion of village residents with chronic HBV infection at the end of follow-up, along with interaction terms involving time. Significance of 1 factor alone, such as age or sex, is called a main effect and is not of primary interest for this presentation. Of primary interest are the interaction terms between time and other factors. A significant interaction of time with another variable, such as sex, indicates that the decline in anti-HBs level differed between males and females. We obtained parameter estimates by using restricted maximum likelihood. We used an unstructured covariance matrix to account for dependence of observations across time within individuals. Backward elimination of statistically nonsignificant terms yielded a final model of main effects and time interaction terms. If the time interaction term was statistically significant, the main effect term remained in the model regardless of statistical significance. We used the Wald chi-square statistic to test covariates. Contrast tests were 2-sided, and an level of 0.05 was required. We used residual plots to evaluate model fit. A secondary outcome was a boost in anti-HBs level at the 11- or 15-year follow-up among persons without additional doses of vaccine. We used the chi-square test or the CochranMantelHaenszel test to compare age and sex of persons with a booster response to those of persons without a booster response at both follow-up years. All P values were exact where appropriate and were 2-sided; results were considered statistically significant at the 0.05 level. We conducted analyses by using StatXact4 (Cytel Software Corp., Cambridge, Massachusetts) and SAS software, version 9.1 (SAS Institute, Inc.). Missing Data Throughout the entire study, anti-HBs determinations were observed for 68% of all potential observational time points (Appendix Table 1). The 15 remote rural Alaskan study villages are accessible only by airplane. During each year, study personnel flew into each village for 1 to 2 days and attempted to recruit all available participants. Persons not available or out of the village for the day were considered miss

Bronchiectasis in Alaska Native children: Causes and clinical courses†

Although bronchiectasis has become a rare condition in U.S. children, it is still commonly diagnosed in Alaska Native children in the Yukon Kuskokwim Delta. The prevalence of bronchiectasis has not decreased in persons born during the 1980s as compared with those born in the 1940s. We reviewed case histories of 46 children with bronchiectasis.

Antibody Levels and Protection after Hepatitis B Vaccine: Results of a 22-Year Follow-Up Study and Response to a Booster Dose

BACKGROUND The duration of protection in children and adults (including health care workers) resulting from the hepatitis B vaccine primary series is unknown. METHODS To determine the protection afforded by hepatitis B vaccine, Alaska Native persons who had received plasma-derived hepatitis B vaccine when they were >6 months of age were tested for antibody to hepatitis B surface antigen (anti-HBs) 22 years later. Those with levels <10 mIU/mL received 1 dose of recombinant hepatitis B vaccine and were evaluated on the basis of anti-HBs measurements at 10-14 days, 30-60 days, and 1 year. RESULTS Of 493 participants, 60% (298) had an anti-HBs level >or=10 mIU/mL. A booster dose was administered to 164 persons, and 77% responded with an anti-HBs level >or=10 mIU/mL at 10-14 days, reaching 81% by 60 days. Response to a booster dose was positively correlated with younger age, peak anti-HBs response after primary vaccination, and the presence of detectable anti-HBs before boosting. Considering persons with an anti-HBs level >or=10 mIU/mL at 22 years and those who responded to the booster dose, protection was demonstrated in 87% of the participants. No new acute or chronic hepatitis B virus infections were identified. CONCLUSIONS The protection afforded by primary immunization with plasma-derived hepatitis B vaccine during childhood and adulthood lasts at least 22 years. Booster doses are not needed.

Hepatitis B Virus Genotypes in Alaska Native People with Hepatocellular Carcinoma: Preponderance of Genotype F

BACKGROUND The development of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) infection has been associated with specific HBV genotypes and the presence of specific mutations. METHODS From a cohort of Alaska Native people with chronic HBV infection, we genotyped 47 patients with HCC and 1129 patients without HCC, and we tested patients with HCC and control patients for mutations in the basal core promoter and precore regions. RESULTS Genotype F was found in 68% of patients with HCC, versus 18% of those without HCC (P<.001). For patients with genotype F, the median age at diagnosis of HCC was lower than that for patients with other genotypes (22.5 vs. 60 years, respectively; P=.002). Overall, there were no significant differences in the number of basal core promoter and precore region mutations between patients with HCC and control patients. CONCLUSIONS We found a significant association between genotype F and the development of HCC among Alaska Native people with chronic HBV infection but no significant association between HCC and basal core promoter or precore mutations in genotype F.

Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus.

Some individuals who are chronically infected with hepatitis B virus (HBV) eventually lose hepatitis B surface antigen (HBsAg). Hepatocellular carcinoma (HCC) has been demonstrated to occur in a few patients after loss of HBsAg. Neither factors associated with loss of HBsAg nor the incidence of HCC thereafter have been clearly elucidated. We performed a prospective population‐based cohort study in 1,271 Alaska Native persons with chronic HBV infection followed for an average of 19.6 years to determine factors associated with loss of HBsAg and risk of developing HCC thereafter. HBsAg loss occurred in 158 persons for a rate of HBsAg clearance of 0.7%/year. Older age, but not sex, was associated with clearance of HBsAg, and loss of HBsAg was not associated with any particular HBV genotypes (A, B, C, D, and F) found in this population. Participants were followed for an average of 108.9 months after HBsAg loss. Six patients, two with cirrhosis and four without, developed HCC a mean of 7.3 years after HBsAg clearance (range, 2.0–15.5 years). The incidence of HCC after clearance of HBsAg was 36.8 per 100,000 per year (95% CI 13.5–80.0) which was significantly lower than the rate in those who remained HBsAg‐positive (195.7 cases per 100,000 person‐years of follow‐up [95% CI 141.1–264.5; P < 0.001]). After loss of HBsAg, HBV DNA was detected in the sera of 28 (18%) of those who cleared a median of 3.6 years after clearance. Conclusion: HCC can occur in persons with chronic hepatitis B who have lost HBsAg, even in the absence of cirrhosis. These persons should still be followed with periodic liver ultrasound to detect HCC early. (HEPATOLOGY 2010.)

High Prevalence of Helicobacter pylori in the Alaska Native Population and Association with Low Serum Ferritin Levels in Young Adults

ABSTRACT Iron deficiency anemia is a common public health problem in the Alaska Native population. Yet, a clear etiology has eluded researchers for decades. Previous studies suggested a link betweenHelicobacter pylori infection, gastrointestinal blood loss due to hemorrhagic gastritis, and generalized iron deficiency anemia in adult Alaska Natives. Therefore, we examined the association between the prevalence of H. pylori-specific immunoglobulin G (IgG) and serum ferritin levels, a marker of iron deficiency. A random sample of 2,080 serum samples from Alaska Native residents drawn between 1980 and 1986 from residents in 13 regions was selected, and the samples were stratified by age, sex, and region. Overall, 75% were positive for H. pylori-specific IgG. The rate of H. pylori seropositivity increased with age; by age 14 years, 78% of the residents were positive. There were no gender differences inH. pylori seropositivity. However, marked regional differences were observed. Serum ferritin levels of <12 ng/ml were found most commonly among persons <20 years of age and among women of childbearing age. A significant association between low serum ferritin levels and prevalence of H. pylori-specific IgG was found, particularly for people aged less than 20 years. H. pylorimay be a factor contributing to the iron deficiency anemia in the Alaska Native population.

Elimination of New Chronic Hepatitis B Virus Infections: Results of the Alaska Immunization Program

An immunization assessment and a serologic survey were conducted to evaluate the effectiveness of a hepatitis B immunization program in eliminating hepatitis B virus (HBV) transmission among Alaska Natives in a region in which HBV infection is endemic. Hepatitis B vaccine coverage was 93% among 567 children </=10 years old residing in the study villages, and catch-up vaccine coverage among 582 susceptible persons 11-30 years old was 62%. None of 271 tested children </=10 years old were chronically infected with HBV, and just 4 (1.5%) had evidence of resolved infection. In contrast, 16% of 332 persons 11-30 years old (those born before implementation of routine infant hepatitis B vaccination) were chronically infected. A hepatitis B immunization program that includes prevention of perinatal HBV infection, routine infant vaccination, and catch-up vaccination of older children and adults can eliminate new chronic HBV infections in a population with a high rate of chronic infection.

The Relationship Between In-Home Water Service and the Risk of Respiratory Tract, Skin, and Gastrointestinal Tract Infections Among Rural Alaska Natives

OBJECTIVES We investigated the relationship between the presence of in-home piped water and wastewater services and hospitalization rates for respiratory tract, skin, and gastrointestinal tract infections in rural Alaska. METHODS We determined in-home water service and hospitalizations for selected infectious diseases among Alaska Natives by region during 2000 to 2004. Within 1 region, infant respiratory hospitalizations and skin infections for all ages were compared by village-level water services. RESULTS Regions with a lower proportion of home water service had significantly higher hospitalization rates for pneumonia and influenza (rate ratio [RR] = 2.5), skin or soft tissue infection (RR = 1.9), and respiratory syncytial virus (RR = 3.4 among those younger than 5 years) than did higher-service regions. Within 1 region, infants from villages with less than 10% of homes served had higher hospitalization rates for pneumonia (RR = 1.3) and respiratory syncytial virus (RR = 1.2) than did infants from villages with more than 80% served. Outpatient Staphylococcus aureus infections (RR = 5.1, all ages) and skin infection hospitalizations (RR = 2.7, all ages) were higher in low-service than in high-service villages. CONCLUSIONS Higher respiratory and skin infection rates were associated with a lack of in-home water service. This disparity should be addressed through sanitation infrastructure improvements.

Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska.

Before vaccination, Alaska Natives experienced very high rates of invasive Haemophilus influenzae type b (Hib) disease and carriage. Vaccination with Hib conjugate vaccine PRP-OMP (polyribosylribitol phosphate Neisseria meningitidis outer membrane protein) began in 1991 and resulted in a sharp decline in cases. In 1996, after switching to a different Hib conjugate vaccine, DTP-HbOC (which combines diphtheria-tetanus-whole cell pertussis vaccines with HbOC [Hib oligosaccharide CRM197]), cases of invasive Hib disease increased, suggesting ongoing Hib transmission despite widespread vaccination. To determine the prevalence of and risk factors for carriage, a cross-sectional study of oropharyngeal Hib carriage was conducted among Alaska Native children aged 1-5 years in remote southwestern Alaska. Of 496 children with swabs taken, 46 (9.3%) were colonized with Hib. Carriage rates varied by village from 2.2% to 13.2% and by age from 6.1% in 1-year-olds to 14.7% in 5-year-olds. Crowding was associated with Hib carriage. Widespread vaccination with PRP-OMP Hib conjugate vaccine did not eliminate carriage in this population of Alaska Natives, and ongoing carriage contributed to disease resurgence.

Viral respiratory infections in hospitalized and community control children in Alaska

Respiratory syncytial virus (RSV) in Alaska Native children from the Yukon Kuskokwim (YK) Delta is associated with a hospitalization rate five times higher than that reported for the general US child population. The role of other viral respiratory pathogens has not been studied in this population. YK Delta children <3 years of age hospitalized with respiratory infections and same aged community control children were prospectively enrolled between October 2005 and September 2007. Polymerase chain reaction detection of viruses was performed on nasopharyngeal samples. Characteristics of hospitalized and asymptomatic control children were analyzed. From October 2005 to September 2007, 440 hospitalized and 425 control children were analyzed. Respiratory viruses were detected in 90% (395) of hospitalized children: 194 (44%) rhinovirus, 131 (30%) adenovirus, 102 (23%) RSV, 77 (18%) para influenza viruses (PIV), 66 (15%) human metapneumovirus (hMPV), 23 (5%) influenza, and 25 (6%) coronavirus. Fifty‐two percent (221) of control children had a virus detected, most commonly rhinovirus (33%), and adenovirus (16%). RSV, PIV, hMPV, and influenza were significantly more common in hospitalized cases than control children, but rhinovirus, adenovirus, and coronavirus were not. RSV and hMPV were associated with higher severity of illness. In this study, RSV remains the most important virus associated with respiratory hospitalization, although hMPV and PIV were also common. RSV and hMPV were associated with more severe illness. Rhinovirus and adenovirus were detected in two‐thirds of hospitalized children, but their frequent detection in control children made their role in respiratory hospitalization uncertain. J. Med. Virol. 82:1282–1290, 2010.